TY  - JOUR
AU  - Rugo, Hope S
AU  - Kabos, Peter
AU  - Beck, J Thad
AU  - Jerusalem, Guy
AU  - Wildiers, Hans
AU  - Sevillano, Elena
AU  - Paz Ares, Luis Gonzaga
AU  - Chisamore, Michael J
AU  - Chapman, Sonya C
AU  - Hossain, Anwar M
AU  - Chen, Yanyun
AU  - Tolaney, Sara M
PY  - 2022
DO  - 10.1038/s41523-022-00482-2
SN  - 2374-4677
UR  - http://hdl.handle.net/20.500.12105/16137
AB  - This nonrandomized, open-label, multi-cohort Phase 1b study (NCT02779751) investigated the safety and efficacy of abemaciclib plus pembrolizumab with/without anastrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor...
LA  - eng
PB  - Nature Publishing Group
KW  - INHIBITOR
KW  - EFFICACY
KW  - CRITERIA
KW  - CDK4
TI  - Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study.
TY  - journal article
ER  -